Ensysce Biosciences announced this week the publication of data showing that its carbon nanotube technology can be used to deliver siRNAs.
According to the company, the findings show that single-walled carbon nanotubes can protect siRNAs in circulation and deliver them into tumors in vivo. The paper was published in the journal Materials.
With funding of up to $1.5 million from the State of Texas Emerging Technology Fund, Ensysce said it aims to move the RNAi delivery technology into phase I testing in the next 12 to 18 months.